erythrosine has been researched along with cardiovascular agents in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasinoff, BB | 1 |
| Hasinoff, BB; Schroeder, PE | 1 |
| Barnes, C; Biedermann, J; Garcia-Rill, E; Good, C; Kobayashi, T; Skinner, RD | 1 |
| Chiang Boey, FY; Huang, CL; Kumar, S; Loo, JS; Steele, TW; Venkatraman, SS; Widjaja, E | 1 |
4 other study(ies) available for erythrosine and cardiovascular agents
| Article | Year |
|---|---|
Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Ethylenediamines; Extracorporeal Membrane Oxygenation; Fluoresceins; Fluorescent Dyes; Glycine; Hypoxia; Ion Transport; L-Lactate Dehydrogenase; Models, Cardiovascular; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Razoxane; Time Factors; Treatment Failure | 2002 |
The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Topics: Animals; Biotransformation; Cardiovascular Agents; Chelating Agents; Chromatography, High Pressure Liquid; Ethylenediamines; Fluoresceins; Glycine; Half-Life; Indicators and Reagents; Infusions, Intravenous; Iron; Male; Molecular Structure; Rats; Rats, Sprague-Dawley; Razoxane | 2002 |
Developmental changes in pedunculopontine nucleus (PPN) neurons.
Topics: Action Potentials; Age Factors; Analysis of Variance; Animals; Animals, Newborn; Avidin; Cardiovascular Agents; Cell Count; Cell Size; Female; Fluoresceins; Immunohistochemistry; In Vitro Techniques; Male; Membrane Potentials; NADP; Neurons; Pregnancy; Pyrimidines; Rats; Rats, Sprague-Dawley; Sodium Channel Blockers; Tegmentum Mesencephali; Tetrodotoxin; Xanthenes | 2004 |
High-throughput screening of PLGA thin films utilizing hydrophobic fluorescent dyes for hydrophobic drug compounds.
Topics: Cardiovascular Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Coated Materials, Biocompatible; Coumarins; Delayed-Action Preparations; Drug Carriers; Fluoresceins; Fluorescent Dyes; High-Throughput Screening Assays; Hydrophobic and Hydrophilic Interactions; Kinetics; Lactic Acid; Magnetic Resonance Spectroscopy; Microscopy; Microscopy, Electron, Scanning; Molecular Structure; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rhodamines; Solubility; Spectrometry, Fluorescence; Spectrum Analysis, Raman; Surface Properties; Technology, Pharmaceutical; Thiazoles | 2011 |